JP6449765B2 - 腫瘍組織における免疫細胞を定量するための方法及びその応用 - Google Patents

腫瘍組織における免疫細胞を定量するための方法及びその応用 Download PDF

Info

Publication number
JP6449765B2
JP6449765B2 JP2015516637A JP2015516637A JP6449765B2 JP 6449765 B2 JP6449765 B2 JP 6449765B2 JP 2015516637 A JP2015516637 A JP 2015516637A JP 2015516637 A JP2015516637 A JP 2015516637A JP 6449765 B2 JP6449765 B2 JP 6449765B2
Authority
JP
Japan
Prior art keywords
cells
tumor
stained
stained cells
density
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015516637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525349A5 (enExample
JP2015525349A (ja
Inventor
ギャロン,ジェローム
パージュ,フランク
ムレチニック,ベルンハルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Universite Paris Descartes
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Universite Paris Descartes filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of JP2015525349A publication Critical patent/JP2015525349A/ja
Publication of JP2015525349A5 publication Critical patent/JP2015525349A5/ja
Application granted granted Critical
Publication of JP6449765B2 publication Critical patent/JP6449765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015516637A 2012-06-14 2013-06-14 腫瘍組織における免疫細胞を定量するための方法及びその応用 Active JP6449765B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2012001446 2012-06-14
IBPCT/IB2012/001446 2012-06-14
PCT/EP2013/062405 WO2013186374A1 (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Publications (3)

Publication Number Publication Date
JP2015525349A JP2015525349A (ja) 2015-09-03
JP2015525349A5 JP2015525349A5 (enExample) 2016-07-14
JP6449765B2 true JP6449765B2 (ja) 2019-01-09

Family

ID=46881097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516637A Active JP6449765B2 (ja) 2012-06-14 2013-06-14 腫瘍組織における免疫細胞を定量するための方法及びその応用

Country Status (13)

Country Link
US (1) US10317408B2 (enExample)
EP (1) EP2861986B1 (enExample)
JP (1) JP6449765B2 (enExample)
KR (1) KR102179848B1 (enExample)
CN (1) CN104541167B (enExample)
AU (1) AU2013276470B2 (enExample)
BR (1) BR112014031143B8 (enExample)
CA (1) CA2873278C (enExample)
DE (1) DE13731071T1 (enExample)
ES (1) ES2902879T3 (enExample)
IL (1) IL235738B (enExample)
SG (1) SG11201408107RA (enExample)
WO (1) WO2013186374A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2701092T5 (es) 2014-02-24 2022-05-12 Ventana Med Syst Inc Procedimientos, kits y sistemas para puntuar la respuesta inmunitaria al cáncer por detección simultánea de CD3, CD8, CD20 y FOXP3
AU2015310886A1 (en) * 2014-09-03 2017-02-02 Ventana Medical Systems, Inc. Systems and methods for calculating immune scores
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
US10034901B2 (en) 2015-01-22 2018-07-31 University Of Massachusetts Cancer immunotherapy
EP3365063B1 (en) * 2015-10-23 2024-04-24 Novartis AG Method of scoring a sample comprising tumor tissue
CN109690314B (zh) * 2016-05-09 2022-08-02 法国国家卫生及研究医学协会 患有实体癌症的患者的分类方法
EP3889893B1 (en) * 2016-05-18 2022-03-30 F. Hoffmann-La Roche AG Tumor proximity measure
US12158399B2 (en) * 2016-08-05 2024-12-03 Duke University CaMKK2 inhibitor compositions and methods of using the same
US11048911B2 (en) * 2016-10-27 2021-06-29 Koninklijke Philips N.V. Apparatus for determining cellular composition information in one or more tissue samples
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
CN106846310A (zh) * 2017-01-19 2017-06-13 宁波江丰生物信息技术有限公司 一种基于免疫组化技术的病理辅助分析方法
EP3659110A1 (en) 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
DK3746790T3 (da) 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
WO2020161125A1 (en) * 2019-02-05 2020-08-13 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer
WO2020245155A1 (en) 2019-06-03 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating a treatment regimen
IL291748A (en) 2019-11-07 2022-06-01 Oncxerna Therapeutics Inc Classification of growth microenvironments
CN111551546B (zh) * 2020-06-01 2023-01-03 南京瑟斯检测科技有限公司 一种基于光学微腔结构超材料的免疫组化便捷检测方法
WO2022002873A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
EP4172628A1 (en) * 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
TWI838687B (zh) * 2021-01-30 2024-04-11 奇美醫療財團法人奇美醫院 評估腫瘤標本免疫狀態的方法
CN113092202A (zh) * 2021-03-25 2021-07-09 上海福君基因生物科技有限公司 一种胃癌预后预测装置
CN113515077A (zh) * 2021-04-23 2021-10-19 重庆德方信息技术有限公司 人体细胞染色过程监控系统及方法
WO2023018085A1 (ko) 2021-08-10 2023-02-16 주식회사 루닛 병리 슬라이드 이미지와 관련된 정보를 출력하는 방법 및 장치
CA3245129A1 (en) 2022-03-17 2023-09-21 Univ Paris Cite METHODS FOR PREDICTING RESPONSE TO IMMUNOTHERAPEUTIC TREATMENT IN A CANCER PATIENT
WO2024197157A1 (en) 2023-03-21 2024-09-26 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
CN116646088B (zh) * 2023-07-27 2023-12-01 广东省人民医院 一种预测方法、装置、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0864082B1 (en) * 1995-11-30 2003-04-02 Chromavision Medical Systems, Inc. Method for automated image analysis of biological specimens
US20070141711A1 (en) * 2005-12-19 2007-06-21 Randy Stephens Automated lean methods in anatomical pathology
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2335221B8 (en) * 2008-09-16 2016-05-25 Novartis AG Reproducible quantification of biomarker expression
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images

Also Published As

Publication number Publication date
DE13731071T1 (de) 2016-08-18
EP2861986B1 (en) 2021-11-10
BR112014031143A2 (pt) 2017-08-08
IL235738A0 (en) 2015-01-29
CN104541167B (zh) 2018-05-01
KR102179848B1 (ko) 2020-11-17
ES2902879T3 (es) 2022-03-30
US20150153349A1 (en) 2015-06-04
SG11201408107RA (en) 2015-01-29
BR112014031143B1 (pt) 2022-03-03
EP2861986A1 (en) 2015-04-22
KR20150023760A (ko) 2015-03-05
JP2015525349A (ja) 2015-09-03
IL235738B (en) 2019-02-28
CA2873278A1 (en) 2013-12-19
AU2013276470A1 (en) 2014-11-27
AU2013276470B2 (en) 2018-06-07
US10317408B2 (en) 2019-06-11
CA2873278C (en) 2021-10-26
BR112014031143B8 (pt) 2022-11-22
WO2013186374A1 (en) 2013-12-19
CN104541167A (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
JP6449765B2 (ja) 腫瘍組織における免疫細胞を定量するための方法及びその応用
US20220051804A1 (en) Image Analysis for Breast Cancer Prognosis
Fox et al. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis
JP5866362B2 (ja) 画像解析による固形腫瘍進行の予後検査
EP3117259B1 (en) Assessment of staining quality
Ahn et al. Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens.
JP2024150478A (ja) 距離に基づく組織状態の決定
US20240310379A1 (en) A method for measuring a prognostic marker in prostate cancer or in breast cancer
JP2019534451A (ja) 1つ又は複数の組織サンプルにおける細胞組成情報を決定する装置
JP2015525358A (ja) 組織切片中の単一細胞におけるマーカー定量
Bae et al. HER2 status by standardized immunohistochemistry and silver-enhanced in situ hybridization in Korean breast cancer
WO2017171720A1 (en) Digital image analysis of inflammatory cells and mediators of inflammation
Tobin et al. Automated image analysis of cyclin D1 protein expression in invasive lobular breast carcinoma provides independent prognostic information
Miller et al. Objective analysis of cancer stem cell marker expression using immunohistochemistry
CN110534202A (zh) 一种针对Sox10在三阴性乳腺癌中的表达进行分析的系统
Stolnicu Prognostic and predictive factors in breast carcinoma
Glajcar et al. Application of tissue microarrays for receptor immunohistochemistry in breast carcinoma
RU2664671C1 (ru) Способ прогноза рака молочной железы
CN115602313A (zh) 用于疾病疗效与生存预后预测的生物标志物及其用途
TWM653792U (zh) Ai數位病理影像辨識系統
Pajor Automated image cytometry for diagnosing bladder cancer by detecting genetically aberrant cells from voided urine via molecular cytogenetics
Müller Sentinel Lymph

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181206

R150 Certificate of patent or registration of utility model

Ref document number: 6449765

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250